-
Analyst Opinions
NewUnited States (US) Wealth Management – High Net Worth (HNW) Investors
US Wealth Management Report Overview In the US, men dominate the High Net Worth (HNW) space, accounting for more than 82% of HNWs. The situation is slowly evolving, however, with female HNW investors becoming an increasingly attractive target segment. The US wealth management market report analyzes the investment preferences, service requirements, and portfolio allocation of US HNW investors. The report is based on GlobalData’s proprietary Global Wealth Managers Survey. Key Investment Preferences · Advisory Asset Management · Automated Investment Services...
-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Sector Analysis
NewBronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
Bronchiectasis Market Report Overview The Bronchiectasis market across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) was valued at $1.4 billion in 2023 and the market will grow at a CAGR of more than 3% from 2023 to 2033. The 7MM (China, Japan, the United Kingdom, Spain, Italy, Germany, France, and the US). The market growth is attributed to the launch of brensocatib and an increase in the number of diagnosed prevalent cases of bronchiectasis. Bronchiectasis Market...
-
Product Insights
Anhui Huadian Power Plant (Class Luan Desulfurization Project)
Anhui Huadian Power Plant (Class Luan Desulfurization Project) is a thermal project located in Anhui, China. The project is owned by Anhui Huadian Lu~an Power Generation Company Limited. The project came online in 2014. Empower your strategies with our Anhui Huadian Power Plant (Class Luan Desulfurization Project) report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Consumer Insights
NewMass Affluent Banking in Greater China – Regional Breakdown by Market Trends, Investment Preferences and Competitor Benchmarking
Mass Affluent Banking Market in Greater China Report Overview Emerging affluents and mass affluents make up most of the affluent population in the Greater China region. The population of affluents has been exponential in the last decade in the region. However, the growth is expected to slow down in the upcoming years as the economies mature. Despite low growth, the number of mass affluent customers in the region is exceedingly large, offering a huge market to the financial providers looking...
-
Product Insights
Likelihood of Approval Analysis for Anesthetic Effect
Overview How likely is it that the drugs in Anesthetic Effect will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anesthetic Effect Overview Anesthesia or anaesthesia is a state of controlled, temporary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: TERN-501 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISC-hpNSC in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISC-hpNSC in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISC-hpNSC in Parkinson's Disease Drug Details: ISC-hpNSC is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLN-619 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLN-619 in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLN-619 in Prostate Cancer Drug Details: CLN-619 is under development for...